---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-062733"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T23:00:02.926536+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health enters up to $8.4M Series B Preferred financing with Helena Global

## Summary
- Up to $8.4M from sale of Series B Non-Voting Convertible Preferred at $1,000/share plus warrants for common stock.
- Six tranche closings: initial $700k, then $700k, then $1.75M each for four more; warrants cover 30% of underlying common.
- Series B Preferred: 10% cumulative annual dividend, convertible at 90% of 5-day VWAP (floor $1.294).
- Registration rights: Company to file resale registration statement within 15 days for conversion and warrant shares.
- Stockholder approval required for second tranche and beyond; Exchange Cap of 19.99% of outstanding common.

## SEC filing metadata
- accession: 0000950170-25-062733
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/0000950170-25-062733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/tivc-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-062733
- JSON: https://secwatch.observer/filing/0000950170-25-062733.json
- Plain text: https://secwatch.observer/filing/0000950170-25-062733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.